Eli Lilly just gave investors several reasons to cheer.

Goldman Sachs’ Asad Haider likes the prospects for medical technology companies, mid-cap biotechs, drug distributors.

This story was originally published by TheStatehouseFile.com By Arianna Hunt The Statehouse File December 18, 2024 In a ...

Lawsuits filed in New Jersey are part of hundreds of complaints against UnitedHealthcare, PBMs, and pharmaceutical giants ...

The Richmond company (Nasdaq: BIOA) will get a fraction of the money upfront from Novartis (NYSE: NVS) — up to $20 million, ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

AnaptysBio's rosnilimab faces significant competition and uncertainty. See why ANAB stock's future hinges on Feb 2025 Phase ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 488.46% and ...

(This Dec. 17 story has been corrected to say that the EU regulator reversed its July decision in November to recommend ...

News of Merck’s licensing of Hansoh’s preclinical medicine pressured shares in Viking and other obesity drug developers seen ...

Merck announces a $2.0 billion agreement with Hansoh Pharma. The deal gives it rights to Hansoh's experimental weight-loss ...

Merck signed a deal worth up to $2 billion with Hansoh Pharma to develop and sell the Chinese biotech's oral obesity drug ...